US Pharma MarketingResults show a landmark change that could double survival rates in one of the most difficult oncology diagnoses, but there are still obstacles to overcome.
Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?
<p>Results show a landmark change that could double survival rates in one of the most difficult oncology diagnoses, but there are still obstacles to overcome.</p>
Source: PharmaVoice